TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Vyriad and Mayo Clinic Collaborate to Extend Clinical Trial for T-Cell Lymphoma

Thursday, June 15, 2023

Vyriad, Inc., has recently announced the expansion of an investigator-initiated Phase 1 trial at Mayo Clinic. The trial aims to evaluate the safety and efficacy of Voyager-V1 (VSV-hIFNbeta-NIS) in patients with peripheral T-cell lymphoma (PTCL), following promising initial results. Voyager-V1 is an experimental therapy being jointly developed by Vyriad and Regeneron Pharmaceuticals, Inc. It is an oncolytic virotherapy designed to specifically target and destroy cancer cells while also stimulating the patient's immune system to prevent recurrence.

Dr. Stephen J. Russell, the CEO and Chief Scientific Officer of Vyriad, highlighted the importance of this Phase 1 trial expansion. He emphasized that early results have shown the potential of Voyager-V1 to provide significant benefits to PTCL patients, a group that typically faces a poor prognosis.

PTCLs encompass a heterogeneous group of rare and aggressive diseases characterized by the malignant transformation of T cells. Understanding and studying the various subtypes of PTCL have been recent developments. Currently, first-line therapies for PTCL patients can offer curative potential, but disease recurrence is common for most individuals.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit